| abstract |
The present invention relates to the anhydrous and hydrated forms of Compound 1, which are useful for inhibiting c-Met protein kinase. The present invention also provides pharmaceutically acceptable compositions comprising a compound of formula I and methods of using the compositions in the treatment of proliferative disorders. For example, in certain embodiments, a pharmaceutical composition comprising a compound of the present invention and a pharmaceutically acceptable carrier, adjuvant or vehicle is provided. In another embodiment, a method of treating a proliferative disorder in a patient or reducing the severity of a proliferative disorder is provided. |